We examine efforts to correct cost inequities of oral anti-cancer agents through legislation, and we look at further efforts to reduce the cost of oral chemotherapy via cycle management and waste reduction.
Ali Mcbride, PharmD, MS
Advertisement
Articles by Ali Mcbride, PharmD, MS
The management of patients receiving treatment with oral oncolytics presents challenges such as cost, adherence, monitoring of side effects, and safe handling.
Advertisement
Latest Updated Articles
Oral Oncolytics: Part 1-Financial, Adherence, and Management ChallengesPublished: August 15th 2013 | Updated:
- Oral Oncolytics: Part 2-Legislation Targeting Cost & Access, and Other Initiatives to Reduce Costs
Published: September 15th 2013 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
3
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
4
Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC
5
